Bristol Myers Squibb (NYSE: BMY) reported strong fourth-quarter performance with Q4 2025 non‑GAAP earnings of $1.26 per share—surpassing the consensus estimate of around $1.15—and revenue of $12.5 billion, a modest year-over-year increase of about 1% that outpaced expectations . The company’s growth portfolio fueled this beat, offsetting the continued decline in legacy products and buoying optimism for the year ahead.
4Q 2025 Results: Growth Portfolio Steadying the Ship
Revenue ticked up approximately 1%, landing at $12.5 billion—slightly higher than analysts’ estimates . The standout performer was the growth portfolio, which rose about 16% to reach $7.4 billion and now represents more than half of total revenues .
In contrast, the legacy portfolio continued its downward trend, declining nearly 15% to about $5.1 billion, pressured by generic competition and evolving healthcare policies .
2026 Outlook: Guidance Exceeds Expectations
Management delivered positive guidance for 2026, forecasting revenue between $46 billion and $47.5 billion and adjusted earnings per share of $6.05 to $6.35—both projections outpacing analyst expectations .
CEO Chris Boerner highlighted the strength of key newer drugs:
“Opdualag, Breyanzi and Camzyos each contributed over $1 billion in sales for the full year, while Reblozyl delivered over $2 billion. These differentiated, durable products are still early in their life cycles, with meaningful runway ahead.”
Despite forecasting a slight decline in legacy product revenue, the rising momentum of the growth portfolio is expected to nearly offset that gap .
Market Reaction & Technical Strength
BMY stock rose about 3.3% following the earnings release, significantly outperforming the broader index . From a technical perspective, BMY achieved a robust Relative Strength (RS) Rating of 83, indicating the stock’s strong performance relative to others over the past year .
Yet, investors should note that the stock is considered extended, having broken past a key buy point from a cup-with-handle pattern. Market analysts suggest monitoring support levels near the 50-day and 10-week moving averages .
Pipeline and Strategic Alliances: Engines for Future Growth
Beyond current earnings, Bristol Myers continues to invest heavily in future growth. An $11.1 billion strategic collaboration with BioNTech was announced in June 2025, centered on co-developing BNT327—a bispecific PD-L1/VEGF-A antibody aimed at advancing next-generation cancer therapies. The deal included $1.5 billion upfront, $2 billion in guaranteed payments through 2028, and up to $7.6 billion in milestones .
Additionally, a Phase 3 trial delay for Cobenfy (originally developed by Karuna Therapeutics) triggered a surprising 6% stock rise. The postponement—approved by the FDA—focused on extending patient enrollment after certain trial site data were excluded, signaling positive early results . Analysts estimate that Cobenfy’s Alzheimer’s psychosis indication could eventually generate up to $2.6 billion in peak sales .
Summary: Balancing Risk and Reward
Bristol Myers’ Q4 2025 results illustrate a company in transition. The growth portfolio’s strong advances buffer the decline in legacy drugs, offering a balanced narrative of renewal. The optimistic guidance for 2026, coupled with strategic execution on R&D and partnerships, provides a tone of cautious confidence.
However, ongoing headwinds from generic erosion, trial delays, and macroeconomic uncertainty (e.g., Medicare pricing, foreign exchange) temper enthusiasm. Investors should weigh BMY’s solid growth execution and pipeline strategy against these inherent risks.
FAQs
What drove Bristol Myers’ Q4 2025 earnings beat?
The growth portfolio, up ~16%, offset a 15% revenue drop in legacy drugs. Growth products now account for over half of total revenues.
What is Bristol Myers’ guidance for 2026?
Revenue is projected between $46B–$47.5B, and adjusted EPS between $6.05–$6.35—both above consensus estimates.
How did investors respond to the earnings release?
Shares rose over 3%, thanks to strong performance in newer drugs and encouraging guidance.
What major pipeline deal could boost future growth?
Bristol Myers struck an $11.1B deal with BioNTech for BNT327 cancer therapy development. Initial payment was $1.5B, with more than $7B tied to milestones.
Why did BMY stock rise despite a trial delay?
A Phase 3 trial delay for Cobenfy lifted shares, as the move to boost patient enrollment—approved by the FDA—signaled strong early data and investor confidence.
Is BMY technically strong?
Yes—the stock achieved a high RS Rating of 83, indicating strong relative performance. Still, it’s currently extended, prompting caution for new entrants.